SCHEMBL4982133

SCHEMBL4982133

O=C(O)N1CCC2(CC1)C(=O)Nc1ccc(F)cc12

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 8/20 0.54
IP6K3 Q96PC2 1/20 0.54
IP6K2 Q9UHH9 1/20 0.54
CYP1A2 P05177 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
HTR7 P34969 3/20 0.43
HTR1A P08908 2/20 0.43
HTR2A P28223 2/20 0.43
HTR6 P50406 2/20 0.43
PGR P06401 3/20 0.41
TNKS O95271 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
NR3C2 P08235 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
PIK3CD O00329 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1949004 1.00 IP6K1 (0.54) IP6K1IP6K3IP6K2CYP1A2MAPT
SCHEMBL6875654 0.85 HTR1A (0.43) IP6K1IP6K3IP6K2CYP1A2MAPT
SCHEMBL25315912 0.83 IP6K1 (0.51) IP6K1IP6K3IP6K2HTR7HTR1A
SCHEMBL2268702 0.82 CYP1A2 (0.63) CYP1A2MAPTCYP2C19KMT2AHTR7
SCHEMBL23778370 0.82 HRH3 (0.42) IP6K1IP6K3IP6K2
SCHEMBL4975823 0.82 IP6K1 (0.45) IP6K1IP6K3IP6K2MAPTTNKS
SCHEMBL4975818 0.82 IP6K1 (0.45) IP6K1IP6K3IP6K2MAPTTNKS
SCHEMBL25316954 0.82 IP6K1 (0.52) IP6K1IP6K3IP6K2HTR7HTR1A
SCHEMBL25315085 0.81 IP6K1 (0.51) IP6K1IP6K3IP6K2HTR7HTR1A
SCHEMBL4263460 0.81 IP6K1 (0.51) IP6K1IP6K3IP6K2MAPTPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354925-B2 Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists PFIZER INC. (US) 2008-04-08 US disclosed
US-7279486-B2 Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists PFIZER INC. (US) 2007-10-09 US disclosed
US-20070197500-A1 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain PFIZER, INC. 2007-08-23 US disclosed
US-20050277659-A1 Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists PFIZER JAPAN INC. (JP) 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277659-A1 Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists OPRL1, OGFRL1, ORMDL3 IP6K1 1515/4885IP6K3 2306/4885IP6K2 2221/4885
US-20070197500-A1 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain OPRL1, OPRD1, OPRK1 IP6K1 657/4885IP6K3 1240/4885IP6K2 938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.